PURPOSE: Despite having an excellent prognosis, patients with ductal carcinoma in situ (DCIS) report significant anxiety and depression following diagnosis. This study evaluated psychological morbidity using the Edmonton Symptom Assessment Scale (ESAS) in patients with DCIS compared with women with early-stage invasive breast cancer (EIBC) receiving radiotherapy (RT). METHODS: We identified patients diagnosed with DCIS or EIBC (stage I or II breast cancer) from 2011 to 2017 who had at least one ESAS completed pre- and post-RT. Data on systemic treatment, radiation, patient demographics, and disease stage were extracted from existing databases. Psychological morbidity was evaluated through measurement of depression, anxiety, and overall wellbeing within the ESAS. The Wilcoxon rank-sum test or chi-square test was performed for continuous or categorical variables. RESULTS: This study included 137 women with DCIS and 963 women with EIBC. ESAS was completed on average 28 days before RT (baseline) and 142 days after RT. Baseline ESAS scores showed significantly higher rates of depression among women with EIBC compared with those with DCIS (p = 0.006). Patients with EIBC also reported higher levels of anxiety and lower overall wellbeing than patients with DCIS, but this difference was not statistically significant. Post-RT ESAS scores showed significantly higher anxiety in patients with EIBC compared with DCIS (p = 0.049). Post-RT measures of anxiety and overall wellbeing were higher in patients with EIBC but differences were not statistically significant. CONCLUSION: Women with DCIS experience relatively less psychological morbidity than women with EIBC, pre- and post-RT.
PURPOSE: Despite having an excellent prognosis, patients with ductal carcinoma in situ (DCIS) report significant anxiety and depression following diagnosis. This study evaluated psychological morbidity using the Edmonton Symptom Assessment Scale (ESAS) in patients with DCIS compared with women with early-stage invasive breast cancer (EIBC) receiving radiotherapy (RT). METHODS: We identified patients diagnosed with DCIS or EIBC (stage I or II breast cancer) from 2011 to 2017 who had at least one ESAS completed pre- and post-RT. Data on systemic treatment, radiation, patient demographics, and disease stage were extracted from existing databases. Psychological morbidity was evaluated through measurement of depression, anxiety, and overall wellbeing within the ESAS. The Wilcoxon rank-sum test or chi-square test was performed for continuous or categorical variables. RESULTS: This study included 137 women with DCIS and 963 women with EIBC. ESAS was completed on average 28 days before RT (baseline) and 142 days after RT. Baseline ESAS scores showed significantly higher rates of depression among women with EIBC compared with those with DCIS (p = 0.006). Patients with EIBC also reported higher levels of anxiety and lower overall wellbeing than patients with DCIS, but this difference was not statistically significant. Post-RT ESAS scores showed significantly higher anxiety in patients with EIBC compared with DCIS (p = 0.049). Post-RT measures of anxiety and overall wellbeing were higher in patients with EIBC but differences were not statistically significant. CONCLUSION:Women with DCIS experience relatively less psychological morbidity than women with EIBC, pre- and post-RT.
Entities:
Keywords:
Anxiety; DCIS; Depression; ESAS; Early breast cancer; Quality of life; Radiotherapy
Authors: Madeleine T King; Zoë E Winters; Ivo A Olivotto; Andrew J Spillane; Boon H Chua; Christobel Saunders; A Helen Westenberg; G Bruce Mann; Petrina Burnett; Phyllis Butow; Claudia Rutherford Journal: Eur J Cancer Date: 2016-12-15 Impact factor: 9.162
Authors: Y R B M van Gestel; A C Voogd; A J J M Vingerhoets; F Mols; G A P Nieuwenhuijzen; O J Repelaer van Driel; C L H van Berlo; L V van de Poll-Franse Journal: Eur J Cancer Date: 2006-11-30 Impact factor: 9.162
Authors: Eileen Rakovitch; Edmee Franssen; John Kim; Ida Ackerman; Jean-Philippe Pignol; Lawrence Paszat; Kathleen I Pritchard; Cindy Ho; Donald A Redelmeier Journal: Breast Cancer Res Treat Date: 2003-02 Impact factor: 4.872
Authors: Sophie Lauzier; Elizabeth Maunsell; Pascale Levesque; Myrto Mondor; Jean Robert; André Robidoux; Louise Provencher Journal: Breast Cancer Res Treat Date: 2009-08-04 Impact factor: 4.872
Authors: M L Gregorowitsch; H J G D van den Bongard; D A Young-Afat; J P Pignol; C H van Gils; A M May; H M Verkooijen Journal: Breast Cancer Res Treat Date: 2017-09-11 Impact factor: 4.872
Authors: Kathryn J Ruddy; Meghan E Meyer; Anita Giobbie-Hurder; Karen M Emmons; Jane C Weeks; Eric P Winer; Ann H Partridge Journal: Oncologist Date: 2013-04-08